The Beckman classification stages age-related macular degeneration (AMD) in people older than 55 years.

It uses drusen size and pigment changes within two disc diameters of the fovea.

Because it needs only a dilated examination or color photograph, it suits routine practice.


What the Beckman Classification Measures

An expert committee published the scale in 2013.

Two findings drive staging: the largest druse and any associated pigment change.

Late disease then adds neovascular AMD and geographic atrophy.

Measuring Drusen at the Slit Lamp

The scale uses two thresholds, 63 and 125 microns.

For example, 125 microns roughly matches the width of a large vein at the disc margin.

A druse about half that width approaches 63 microns.

However, magnification varies, so compare each druse with that vein.

Morphology adds information (see soft and hard drusen).

Test your knowledge 10 questions from this article
Choroida · Fundus imaging

Fundus Explorer Pro

Photograph the retinal findings described here with the phone already in your pocket — 22 D optics and built-in illumination in one handheld unit.

From Choroida — the team behind this site

The Five Beckman Classification Stages

  • No aging changes: no drusen and no pigmentary abnormalities
  • Normal aging changes: only drupelets, smaller than 63 microns
  • Early AMD: medium drusen (63 to 125 microns) without pigment abnormalities
  • Intermediate AMD: large drusen, or pigment abnormalities with medium drusen
  • Late AMD: neovascular AMD or any geographic atrophy

Normal Aging and Early AMD

Drupelets are common in older eyes and carry no clinically relevant risk.

Therefore, avoid giving these patients an AMD diagnosis.

Medium drusen define early AMD, and patients usually keep good acuity.

Nevertheless, discuss smoking, diet and periodic examination.

Intermediate AMD in the Beckman Classification

One large druse within the macular zone qualifies.

Pigment changes with at least medium drusen also qualify.

Some patients notice slow dark adaptation despite good acuity.

However, risk varies widely, because bilateral findings carry more weight.

Late AMD: Neovascular Disease and Atrophy

Late AMD includes neovascular disease or geographic atrophy of any size.

Examiners may see subretinal fluid, hemorrhage or a sharply demarcated atrophic patch.

OCT then confirms fluid, neovascular tissue and outer retinal loss.

Foveal involvement is separate, because atrophy can spare the center.

Progression Risk in the Beckman Classification

Five-year risk of late AMD rises about 100-fold across the scale.

It ranges from about 0.5% with normal aging changes to about 50% in the highest-risk group.

These figures describe groups, so they cannot predict one patient’s course.

Comparison With the AREDS Simplified Scale

This scale gives one point per eye for large drusen and one for pigment abnormalities.

Thus, it refines risk within the broad intermediate stage.

Five-year risks for scores 0 to 4 are about 0.5%, 3%, 12%, 25% and 50%.

Supplements and Beckman Classification Stage

AREDS reduced progression in participants with intermediate disease or late AMD in one eye.

Therefore, AREDS-type supplements suit those patients, while early disease lacks comparable evidence.

AREDS2 then supported lutein and zeaxanthin in place of beta-carotene.

Finally, explain that supplements slow risk modestly and do not reverse damage.

Beckman Classification (AMD Stages): Drusen and Counseling

Management of Late Disease

Active neovascular AMD needs prompt anti-VEGF evaluation (see wet vs dry AMD).

Complement inhibitors may slow geographic atrophy growth in selected patients.

However, they do not restore lost vision.

Imaging Limits of the Beckman Classification

The scale predates modern multimodal grading.

Consequently, it does not stage reticular pseudodrusen, which OCT often reveals.

Consensus OCT definitions of atrophy now add structural detail.

Mimics That Distort Staging

For example, basal laminar drusen can appear as numerous small lesions in younger patients.

Pattern dystrophy and adult vitelliform lesions can also mislead.

Therefore, check age, family history, autofluorescence and OCT when the appearance is atypical.

Counseling Patients Using the Beckman Classification

Use plain language first, because many patients equate AMD with blindness.

AMD rarely causes complete blindness, although central vision can decline.

Next, name the stage and describe the approximate risk.

Also teach patients to report new distortion or sudden blur promptly.

At each visit, compare drusen, pigment and OCT with baseline.

Follow-Up After Staging

Examination intervals depend on stage, symptoms and fellow-eye status.

Patients with intermediate disease need clear self-monitoring instructions.

An Amsler grid may help, although a normal grid cannot exclude neovascularization.

Documenting the Beckman Classification Stage

Record the stage separately for each eye, because the fellow eye changes risk.

Also note the largest druse, pigment changes and the imaging used.

Then, compare the next visit with the same baseline photograph or OCT scan.

As a result, small changes become easier to recognize.

Risk Factors That Modify Staging Decisions

  • Smoking, which raises progression risk and is modifiable
  • Family history of AMD, because genetic risk is substantial
  • Older age, since progression risk rises over time
  • Fellow-eye late AMD, which increases risk in the second eye

Pitfalls to Avoid

  • Do not label drupelets as early AMD
  • Do not stage lesions outside the two-disc-diameter zone
  • Avoid estimating drusen size without a reference vessel
  • Do not assume geographic atrophy always involves the fovea
  • Never recommend supplements without checking the stage

All-fit smartphone adapter on a slit lampFundus Explorer Pro smartphone fundus camera
Choroida · Clinical imaging

Document what you see

Two smartphone imaging tools built for everyday clinic use — one for the slit lamp, one for the fundus.

From Choroida — the team behind this site

References

  1. Ferris FL 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844-851.
  2. Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Arch Ophthalmol. 2005;123:1570-1574.
  3. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration. JAMA. 2013;309:2005-2015.
  4. Sadda SR, Guymer R, Holz FG, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT. Ophthalmology. 2018;125:537-548.

Test yourself

A few questions straight from this article.

1 / 10 0 correct
  1. Within what zone are lesions graded in the Beckman classification of AMD?

Ahmed Ophthalmologist

Writes and reviews the clinical articles on Educate. Every post is checked against peer-reviewed sources before it goes live.